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Introduction
Stent thrombosis (ST) is a major concern in the drug-eluting 
stents (DES) era. There are several reports of stent thrombosis 
occurring up to five years after stent implantation. We report 
the case of a sixty eight-year-old woman with very late 
ST presenting as acute ST-elevation myocardial infarction 
(STEMI) after stopping antiplatelet therapy eight years past 
DES placement. The long time-to-event of this case brings 
new questions to the controversial aspects of optimal follow-
up time and the safety of antiplatelet therapy cessation after 
recommended times are met in patients with DES.
Case Report
We present the case of a sixty eight-year-old woman with 
a history of multiple cardiovascular risk factors (diabetes, 
hypertension and hyperlipidemia) and a previous acute 
coronary syndrome (ACS) in 2003. At that time the coronary 
angiogram revealed total occlusion of the left anterior 
descending artery (LAD), long sub-occlusive stenosis of the 
left circumflex artery (LCX) and irregularities of the right 
coronary artery. Two sirolimus-eluting stents (2,5*28mm 
and 2,25*28mm) were implanted in the LAD and another 
two (2,25*28mm and 2,25*13mm) in the LCX, with a final 
Thrombolysis in Myocardial Infarction (TIMI) flow grade of 
III. The echocardiogram showed akinetic apical segment and 
preserved left ventricle function.
During the follow-up (2008) aspirin was changed to 
clopidogrel due to gastrointestinal side effects. She was on 
clopidogrel in addition to rosuvastatin, lisinopril, carvedilol 
and oral antidiabetics since then and remained asymptomatic 
until December 2010 when she described effort-related chest 
pain. A treadmill exercise stress test was performed and no 
ST-segment changes were observed but the patient referred 
chest pain at the peak of stress test. A myocardial perfusion 
scintigraphy showed normal left ventricle function (ejection 
fraction of 57%) and an extensive anterior, septal and apical 
defect, without reversibility.
In July 2011 she was admitted to the emergency 
department with chest pain associated with nausea. Five 
days earlier, she had voluntary stopped clopidogrel after 
analgesic prescription for arthralgias. Physical examination was 
unremarkable except for diaphoresis.  The electrocardiogram 
showed sinus rhythm, Q waves from V2-V4 and ST segment 
elevation in leads V2 through V5, DII, DIII and AVF (figure 1). 
The diagnosis of anterior acute STEMI was made and four 
hours after symptom onset she was referred for primary 
percutaneous coronary intervention (PCI). The coronary 
angiogram revealed thrombotic occlusion of the medium 
LAD at the site of previous stent placement (figure 2, left 
panel), patency of LCX stents and irregularities of the other 
coronary segments. Aspiration thrombectomy was performed, 
which achieved a good result with TIMI 3 flow (figure 2, right 
panel). Eptifibatide infusion was started and she underwent 
new coronary angiography forty eight hours later showing LAD 
irregularities, maintaining TIMI 3 flow. She had no adverse 
events during hospitalization and was discharged five days 
later on dual antiplatelet therapy.
Discussion
Coronary artery stents are widely used in patients 
undergoing PCI. DES dramatically reduce restenosis rates 
with a significant reduction of repeat revascularizations, 
when compared to bare-metal stents (BMS)1. However, ST 
is a major concern, as the clinical consequences of ST are 
generally catastrophic, almost always presenting as death or 
large non-fatal myocardial infarction, usually with ST-segment 
elevation2.  Most cases of ST occur within the first thirty 
days after stent placement, but the risk is continuous at a 
rate of 0,6% per year for at least four years after stenting3. 
The longest time-to-ST case reports the authors found 
happened four to five years after stent deployment4,5. 
Recently the results of the DESERT registry were presented. 
It included 922 patients from more than 40 clinical centers 
who implanted first-generation DES, mainly Cypher and 
Taxus stents and experienced definite late or very late ST. 
The majority of the late ST occurred after 1 year (75%) and 
continued to occur up to 7.3 years6, extending the risk period 
even further. Our case report has twice the time-to-event of 
the other cases, and presented even later than the 7.3 years 
of the largest registry of DES thrombosis (DESERT), making 
the optimal follow-up duration of patients with DES stents 
even more uncertain.
The main pathologic mechanism of ST is delayed arterial 
healing characterized by incomplete endothelialization as 
showed by analysis of 40 consecutive autopsies of patients DOI: 10.5935/abc.20130095
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Figure 1 - Electrocardiogram at the time of presentation showing Q waves from V2-V4 and ST segment elevation in leads V2 through V5, DII, DIII and AVF.
Figure 2 - View of the LAD showing thrombotic occlusion of the medium LAD at the site of previous stent placement (left panel) and complete reperfusion following 
aspiration thrombectomy (right panel). LAD (left anterior descending artery).
with stents – complete endothelialization of BMS occurred by 
six to seven months, whereas incomplete endothelialization 
persisted in the DES group beyond forty months7. Emerging 
evidence suggests in-stent neoatherosclerosis as another 
important substrate for late ST8. Although the precise mechanisms 
of neoatherosclerotic development remain unknown, the 
incidence of neoatherosclerosis is greater in DES lesions (31% 
vs 16% in BMS) and occurs earlier (420 days [361 to 683 days] 
vs. 2,160 days [1,800 to 2,880 days])8. Neoatherosclerosis is 
a probable explanation for ST during the first years after DES 
placement, but probably a less important mechanism for this 
case report with a much longer time-to-event. There are other 
risk factors concurring to ST including procedural aspects such as 
bifurcation stenting and incomplete stent apposition (ISA). ISA is 
defined as the absence of stent strut contact with the underlying 
vessel wall (not overlying a side branch). Late acquired ISA 
has been observed in 7% to 21% of DES9 and positive arterial 
remodeling with an increase of the external elastic membrane out 
of proportion to changes in plaque and media appears to be its 
most likely mechanism9. This patient had two 2,25*28mm stents 
in the LAD which may correspond to undersized stents. DES 
implantation occurred in context of ACS following a thrombotic 
occlusion of the LAD, the decrease of plaque with dissolution of 
jailed thrombus may have limited the stent size choice, with later 
influence in the occurrence of ISA. Also, withdrawal of antiplatelet 
therapy seems to be an important risk factor for ST. The median 
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time from dual antiplatelet therapy cessation to a thrombosis-
related clinical event is seven days (with a range of 3 to 150 days)4. 
In clinical practice it isn’t unusual to have to consider antiplatelet 
therapy cessation due to, for example, surgery or gastrointestinal 
bleeding. In this case report the patient was on single antiplatelet 
therapy until the event occurred five days after she voluntarily 
stopped medication even eight years after stent implantation. This 
raises questions about the safety of discontinuation of therapy 
even after the recommended times are met.
Conclusion
Our case report draws the attention to the serious clinical 
implications of ST, highlighting the need to consider its 
possibility many years after stent implantation. As one of 
the longest reported time-to-event case it shows how the 
potential risk of ST should always be considered when 
antiplatelet therapy cessation is contemplated in patients 
with DES.
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